All In MedTech

FDA Clearance Tracker · P140032-S001

Remodulin

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 27, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 27, 2018

Approved

Time to decision

186 days

Received Jan 22, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P140032-S001
Device name
Remodulin
Applicant location
Minneapolis, MN
Received
Jan 22, 2018
Decided
Jul 27, 2018
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P140032

Device type

Device class
Class III

Every decision under product code LKK

FDA's approval statement

As written in FDA's record.

Post-Approval Study protocol as a condition of approval for P140032 of the Medtronic Implantable System for Remodulin (ISR) for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P140032.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.